Mechanism of Action
Cocoa flavanols act mainly on the endothelium, the thin layer of cells lining the inside of blood vessels. Their active compound, epicatechin, supports the production of nitric oxide, a signalling molecule the endothelium releases to regulate the tone of the vessel wall.
This production tends to decline with age. It is on this pathway that trials measure dilation of the arm artery.
This action does not stop at the large arteries. Skin trials record increased circulation in the tissues of the skin. This sheds light on the density and elasticity measures recorded at the same time.
Flavanols belong to the polyphenols, a family of plant compounds found in many fruits and plants. Their absorption occurs in the small intestine and depends heavily on how much the source cocoa has been processed.
Key Benefits
- Strong
Blood vessels that stay supple: cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow. This effect is obtained with a daily intake of 200 mg. In a cross-over trial in twenty healthy adults, dilation of the arm artery rose from 6.2% without intake to 7.6% at 200 mg per day, after one week of use.
- Moderate
Less rigid arteries: in the same trial, stiffness of the large arteries and levels of endothelin-1, a molecule that narrows vessels, fell as the dose rose from 80 to 800 mg per day. Each level was tested for one week in the same twenty participants.
- Moderate
Skin that is more resilient and smoother: in women taking 326 mg of flavanols per day, redness triggered by controlled UV exposure fell by 15% at six weeks and 25% at twelve weeks. A second trial, at 320 mg per day for twenty-four weeks in women aged 43 to 86 with photo-aged skin, measured less pronounced wrinkles and better elasticity. The effect concerns these two measures, not hydration.
Dosage & Forms
Cocoa flavanols are measured in milligrams of total flavanols, of which epicatechin is the reference fraction. Dietary cocoa contains highly variable amounts: roasting and alkalisation, a process that softens cocoa's taste, destroy a large share. An ordinary dark chocolate bar therefore provides only an inconsistent fraction.
Vascular function is documented from 200 mg of flavanols per day. A synthesis of eighteen trial arms places the maximum effect on arterial dilation much higher, around 710 mg. The dose-response curve flattens beyond that point. The two skin trials were run at 320 and 326 mg per day.
The amount of flavanols cannot be inferred from the weight of the extract. At equal weight, two differently standardised extracts deliver very different amounts.
In the Singular Formula
Inclusion rationale
Native polyphenols of the cocoa bean (Theobroma cacao), flavanols are among the best-documented plant compounds for vascular function, led by epicatechin. Industrial cocoa processing (roasting, alkalisation) destroys most of this fraction, which is why a standardised extract is preferred over ordinary cocoa. Cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow; this effect is obtained with a daily intake of 200 mg. A cross-over trial in healthy adults compared five daily intakes: dilation of the arm artery improved from 80 mg, then continued to rise with the dose. The formula delivers 350 mg, a level chosen to also exceed the threshold of the two trials measuring, in women, skin less reactive to UV and less pronounced wrinkles. In the formula, cocoa flavanols extend the vascular axis alongside omega-3 (EPA+DHA) and black garlic, and join astaxanthin on skin resilience.
Selected form
CocoActiv® is a cocoa bean (Theobroma cacao) extract standardised to at least 30% cocoa flavanols. Among these native polyphenols, epicatechin is the most studied. The extraction process preserves the flavanol fraction that industrial cocoa processing, particularly roasting and alkalisation, largely degrades. This specification provides consistent content from batch to batch. Powder with no excipient.
Formula dosage
0 to 350 mg.
Dose expressed as active substance, excluding excipients and carriers of the raw material.
Synergies in the formula
Safety & Precautions
Cocoa flavanols have a favourable safety profile at nutritional doses. The standardised extract contains theobromine, an alkaloid naturally present in cocoa. At the dose used it amounts to around 60 to 105 mg per day, the order of magnitude of a cup of cocoa. People sensitive to methylxanthines (theobromine, caffeine) may prefer taking it earlier in the day.
Supplementation is not recommended during pregnancy and breastfeeding. Clinical work has associated high maternal polyphenol intake in the third trimester with a reversible change in the circulation of the foetus. No benefit has been measured in pregnant women either.
Low fat cocoa extract is authorised as a novel food in the European Union. That authorisation sets a ceiling: no more than 600 mg of cocoa flavanols per day. The largest clinical record covers 21,442 adults followed for 3.6 years at 500 mg per day, with no safety signal.
The skin measures concern redness recorded in a laboratory under controlled UV. They are not a substitute for sun protection.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Grassi D et al. | 2015 | Randomised Controlled Trial | Journal of Hypertension | View on PubMed |
Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals Randomised double-blind cross-over trial in twenty healthy adults, with five daily intakes each tested for one week: 0, 80, 200, 500 and 800 mg of flavanols. Dilation of the arm artery improved from 80 mg and increased with dose; arterial stiffness and endothelin-1 fell in the same way. Small sample and short duration per level; two co-authors are employees of the extract manufacturer. | ||||
| Heinrich U et al. | 2006 | Randomised Controlled Trial | Journal of Nutrition | View on PubMed |
Long-term ingestion of high flavanol cocoa provides photoprotection against UV-induced erythema and improves skin condition in women Controlled trial in women receiving 326 mg of flavanols per day versus 27 mg, over twelve weeks. Redness triggered by controlled UV exposure fell by 15% at six weeks and 25% at twelve weeks in the high-flavanol group, with no change in the control group. Skin density and hydration also improved. | ||||
| Yoon HS et al. | 2016 | Randomised Controlled Trial | Journal of Nutrition | View on PubMed |
Cocoa Flavanol Supplementation Influences Skin Conditions of Photo-Aged Women: A 24-Week Double-Blind, Randomized, Controlled Trial Randomised double-blind trial over twenty-four weeks in women aged 43 to 86 with photo-aged skin, at 320 mg of flavanols per day versus placebo. The primary endpoint, average wrinkle roughness, improved by 8.7 percentage points against placebo. Elasticity also improved at twelve and twenty-four weeks; hydration and skin barrier were unchanged. | ||||
| Sun Y et al. | 2019 | Meta-analysis | Food & Function | View on PubMed |
Dose-response relationship between cocoa flavanols and human endothelial function: a systematic review and meta-analysis of randomized trials Synthesis of fifteen publications and eighteen trial arms, covering intakes from 80 to 1,248 mg of flavanols per day. Arterial dilation improved by 1.17 percentage points on average, along a bell-shaped curve peaking around 710 mg. The authors note substantial variability and risk-of-bias concerns in a large majority of the included trials. | ||||
| Sesso HD et al. | 2022 | Randomised Controlled Trial | American Journal of Clinical Nutrition | View on PubMed |
Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial The largest trial conducted on these compounds: 21,442 adults receiving 500 mg of flavanols per day or placebo, followed for 3.6 years. It provides the broadest tolerance record available, with no safety signal. The primary endpoint, total cardiovascular events, was not met; the authors call for cautious reading of the secondary endpoints. | ||||